The CRI Technology Impact Award provides seed funding of up to $200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies.

These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.

Get more details and apply